ISB News

Drs. Naeha Subramanian, Leah Rommereim Gilmore, and Ajay Suresh Akhade

Small, Persistent Increase in the Expression of NOD1 May Promote Cancer Risk

ISB researchers have found that a small, persistent increase in the expression of NOD1 could be responsible for higher cancer risks. The research team found that a slight 1.5-fold uptick in NOD1 expression can activate the protein and downstream signaling pathways in a manner similar to vast (30- to 200-fold) overexpression.

CRI iAtlas

CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments

CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.

Priyanka Baloni

Bile Acids Provide More Evidence of the Gut Microbiome’s Effect on Alzheimer’s Disease

ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.

Subramanian and Akhade

How Salmonella Co-Opts the Host Immune System to Conceal Itself

While scientists have long studied bacterial infections, less attention has been paid to how the host immune response affects bacterial gene expression in the body. In a just-published paper in PNAS, ISB researchers detailed how the bacterium Salmonella conceals itself from the host immune system.

Corresponding author and ISB President Dr. Jim Heath and lead author Dr. Yapeng Su.

COVID-19 Immune Response Study Could Lead to More Effective Treatments

Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar.

Dr. Jim Heath and Dr. David Eagleman

David Eagleman and Creating New Senses for Humans

Dr. David Eagleman — bestselling author, TV personality, CEO of Neosensory, adjunct professor at Stanford, TED speaker, and more — was the featured guest at the ISB-Town Hall Seattle event focusing on brain health. His presentation was titled “Can We Create New Senses for Humans?”

Human proteome blueprint

HUPO Releases 10-Year High-Stringency Blueprint of Human Proteome

Like the draft “shotgun” Human Genome Project of the Human Genome Organization (HUGO), the HPP has now reached a significant decadal milestone of more than 90 percent completion of the Human Proteome that is referred to as the human proteome “parts list.”

Overall composition of gut microbiome in participants

Variations in the Microbiome Associated with Health, Disease

ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.

ISB researchers

Unveiling the Guerrilla Warfare Tactics of Mycobacterium Tuberculosis

ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.

ISB’s Dr. Nathan Price Inducted into AIMBE’s College of Fellows

Dr. Nathan Price has been inducted into the American Institute for Medical and Biological Engineering’s (AIMBE) College of Fellows. Price was nominated, reviewed, and elected by peers and members of the College of Fellows for his contributions deriving medical and biological insights from large-scale data analysis and network modeling, and translating those insights to society.

Illustration of a person using a katana to slash a coronavirus in half

Merck, ISB, Swedish Collaborate In Trial to Understand, Treat COVID-19

ISB and Swedish Medical Center launched a study to follow hundreds of patients who contract COVID-19 to learn why those infected have drastically different outcomes. “Each of the COVID-19 patients has a unique lesson to teach us about how the medical and scientific community can respond most effectively to this pandemic,” said ISB President Dr. Jim Heath, who co-leads the study.

Education resources

During Coronavirus Outbreak, Free Online Resources for Stuck-At-Home K-12 Students

ISB Education is continually working to identify effective resources to support student learning. In response to the coronavirus outbreak and the closure of K-12 schools across the nation, we recognize that many schools and families are looking for resources to meet the needs of students.

CDC Coronavirus Image

ISB Statement Concerning the Ongoing Coronavirus Outbreak

ISB is committed to the health and safety of our research and administrative staff. Some of our scientists are conducting important COVID-19 research. Otherwise, ISB is adhering to Governor Jay Inslee’s stay-at-home orders. For the latest coronavirus information, please monitor the Centers for Disease Control and Prevention (CDC) webpage linked from this news item.

soldier

ISB Researchers Seek a Better Way to Identify Chronic Mild Traumatic Brain Injury

Mild traumatic brain injury (mTBI) has been a frequent injury among U.S. combatants, and blast-related mTBI has been called the “signature injury” from military conflicts in Iraq and Afghanistan. ISB researchers are working to develop new methods to identify molecular changes in the blood of war veterans diagnosed with chronic mTBI.

Dr. Christian Diener, postdoc in ISB's Gibbons Lab.

New Modeling Tool Allows Microbiome Researchers to Map Community Ecology to Ecosystem Function

A promising new open-source metabolic modeling tool provides microbiome researchers a path forward in predicting ecosystem function from community structure. News of the software package, called MICOM, was developed in part by researchers in ISB’s Gibbons Lab, and its uses were published in the journal mSystems.

Using Blood to Predict Gut Microbiome Diversity

Predicting the alpha diversity of an individual’s gut microbiome is possible by examining metabolites in the blood. The robust relationship between host metabolome and gut microbiome diversity opens the door for a fast, cheap and reliable blood test to identify individuals with low gut diversity.

Dr. Mary Kay Ross

ISB, BHRI Collaborate to Better Understand Significant Brain Impairment

ISB has entered into a scientific partnership with the Brain Health & Research Institute (BHRI), which opens its doors on September 3 in Seattle. BHRI was created by brain health expert Dr. Mary Kay Ross, and is dedicated to the evaluation, prevention, and treatment of neurodegenerative diseases, including Alzheimer’s Disease and dementia.

The Cancer Paradox

ISB’s Dr. Sui Huang uses the theory of complex systems and applies it to cancer research. In this video Q&A, he discusses the cancer paradox and highlights the importance of understanding the mechanism of what cancer treatments can backfire in order to open a new avenue for therapy and treatments.